DAPA-CKD

Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.

4 304

Schéma

Double-blind RCT, stopped early

Critère

≥50% eGFR decline, ESKD, or renal or CV death

Pertinence

Résultat9.2% vs 14.5%; HR 0.61 (95% CI 0.51–0.72; p<0.001); all-cause mortality HR 0.69.

Heerspink HJL, et al. N Engl J Med. 2020;383(15):1436-1446. 10.1056/NEJMoa2024816

Discussion et critique

Extended SGLT2-inhibitor benefit to non-diabetic CKD; dialysis patients were excluded.